GeneseeqPrime® NGS Tumor Profiling Assay (FFPE) Technical Specifications

Explore the technical specifications of the FDA-cleared GeneseeqPrime® NGS Tumor Profiling Assay (FFPE), an NGS testing kit designed for genomic profiling of solid tumor FFPE samples. The assay covers 400+ cancer-related genes and multiple genomic alteration types and biomarkers, including SNVs, indels, ERBB2 amplification, ALK/ROS1/RET/NTRK1 translocations, MSI, and TMB.

Key Features of GeneseeqPrime® Solid Tumor NGS Panel

• 400+ Cancer-Related Genes
  Broad tumor genomic profiling across 400+ cancer-related genes.
• Multiple Genomic Alteration Types
  Detection of SNVs and indels, ERBB2 amplification, and ALK, ROS1, RET, and NTRK1 translocations.
• MSI & TMB
  Assessment of microsatellite instability (MSI) and tumor mutation burden (TMB).
• FFPE Tumor Samples
  Designed for genomic DNA isolated from formalin-fixed, paraffin-embedded solid tumor tissue.

What’s Inside the Technical Specifications

Download the full technical specifications for detailed information about the GeneseeqPrime® NGS tumor profiling assay, including:

• Intended use and reportable range
• Assay components and sequencing platform
• FFPE specimen and DNA input requirements
• Turnaround time and batch size
• Analytical performance characteristics
• Limit of detection (LOD), PPA, and NPA data
• 400+ cancer-related gene targets
• Implementation, technical support, and laboratory onboarding resources

Download the Technical Specifications

Complete the form below to access the GeneseeqPrime® NGS Tumor Profiling Assay (FFPE) Technical Specifications.